Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1292145 | 0.91 | USP2 (0.46) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL3970403 | 0.91 | PKM (0.49) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL963907 | 0.89 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL28990172 | 0.87 | CYP4F2 (0.49) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL965651 | 0.87 | USP2 (0.51) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL3160087 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL28797839 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL28689933 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL28986539 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL | |
| SCHEMBL17830841 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2CYP4F2CYP4A11RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116113627-A | Ji Yin-indolyl glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | USP2 2239/4885SMN1; SMN2 2262/4885CYP4F2 4398/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | USP2 2239/4885SMN1; SMN2 2262/4885CYP4F2 4398/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | USP2 2239/4885SMN1; SMN2 2262/4885CYP4F2 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.